BioMarin Pharmaceutical Inc. (FRA:BM8)
Germany · Delayed Price · Currency is EUR | Market Cap | 10.97B +14.3% |
| Revenue (ttm) | 2.98B +11.2% |
| Net Income | 63.87M -88.9% |
| EPS | 0.33 -88.9% |
| Shares Out | n/a |
| PE Ratio | 171.71 |
| Forward PE | 10.61 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,000 |
| Open | 56.36 |
| Previous Close | 55.98 |
| Day's Range | 56.36 - 56.90 |
| 52-Week Range | 42.62 - 60.74 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 6, 2026 |
About BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company’s products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NA... [Read more]
Financial Performance
In 2025, BioMarin Pharmaceutical's revenue was $3.22 billion, an increase of 12.87% compared to the previous year's $2.85 billion. Earnings were $348.90 million, a decrease of -18.26%.
Financial numbers in USD Financial StatementsNews
BioMarin to acquire Alesta Therapeutics for $275 million for potential rare bone disease treatment
BioMarin will acquire Alesta Therapeutics for $275 million upfront, and up to an additional $215 million based on milestones. Alesta Therapeutic's lead drug is a potential treatment for hypophosphatas...
BMO starts BioMarin at Outperform, sees slower fade for Voxzogo
BMO Capital initiated coverage of BioMarin (BMRN) with an Outperform rating and $98 price target BioMarin is a profitable rare-disease company with durable enzyme therapies, Voxzogo, and new Amicus as...
BioMarin initiated with an Outperform at BMO Capital
BMO Capital analyst David Lebowitz initiated coverage of BioMarin (BMRN) with an Outperform rating and $98 price target BMO rolled out coverage on nine biotechnology companies, saying each might be…
BioMarin price target lowered to $59 from $60 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on BioMarin (BMRN) to $59 from $60 and keeps a Neutral rating on the shares after the company acquire Alesta for $275M upfront…
BioMarin to acquire Alesta Therapeutics for $275M plus payments
BioMarin (BMRN) has entered into a definitive agreement to acquire Alesta Therapeutics to gain Alesta’s lead clinical-stage asset, ALE1. Alesta plans to spin out all non-ALE1 assets prior to the…
BioMarin to Acquire Alesta Therapeutics to Gain ALE1, a Potential First Oral Therapy for Hypophosphatasia, Adding an Important Clinical Program to BioMarin's Pipeline
BioMarin to pay $275 million upfront, plus additional payments upon achievement of development and regulatory milestones Alesta to spin out all non-ALE1 assets to a new entity and Alesta employees to ...
BioMarin price target raised to $88 from $82 at Piper Sandler
Piper Sandler raised the firm’s price target on BioMarin (BMRN) to $88 from $82 and keeps an Overweight rating on the shares following quarterly results. The firm likes what it…
BioMarin price target raised to $111 from $105 at Barclays
Barclays analyst Eliana Merle raised the firm’s price target on BioMarin (BMRN) to $111 from $105 and keeps an Overweight rating on the shares post the Q2 report. The firm…
BioMarin Pharmaceutical Transcript: Canaccord Genuity's 46th Annual Growth Conference
A rare disease-focused company reported strong Q2 growth, raised full-year guidance, and accelerated its de-leveraging timeline following the Amicus acquisition. Key growth drivers include global expansion of new assets, VOXZOGO's performance, and a robust pipeline, with continued focus on strategic business development.
BioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston
SAN RAFAEL, Calif., Aug. 10, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced management will present at the Canaccord Genuity 46th Annual Growth Conference on Wednesda...
BioMarin price target raised to $114 from $111 at Canaccord
Canaccord analyst Whitney Ijem raised the firm’s price target on BioMarin (BMRN) to $114 from $111 and keeps a Buy rating on the shares. The firm updated its model following…
BioMarin price target raised to $80 from $75 at Wells Fargo
Wells Fargo raised the firm’s price target on BioMarin (BMRN) to $80 from $75 and keeps an Overweight rating on the shares. The firm says the company’s Amicus guidance underscores…
BioMarin price target raised to $86 from $80 at BofA
BofA analyst Jason Zemansky raised the firm’s price target on BioMarin (BMRN) to $86 from $80 and keeps a Buy rating on the shares. BioMarin’s Q2 was a beat and…
BioMarin price target raised to $124 from $119 at Morgan Stanley
Morgan Stanley raised the firm’s price target on BioMarin (BMRN) to $124 from $119 and keeps an Overweight rating on the shares.
BioMarin price target raised to $105 from $100 at Raymond James
Raymond James raised the firm’s price target on BioMarin (BMRN) to $105 from $100 and keeps an Outperform rating on the shares.
BioMarin price target raised to $70 from $68 at Stifel
Stifel raised the firm’s price target on BioMarin (BMRN) to $70 from $68 and keeps a Hold rating on the shares.
BioMarin price target raised to $97 from $95 at Oppenheimer
Oppenheimer raised the firm’s price target on BioMarin (BMRN) to $97 from $95 and keeps an Outperform rating on the shares. The firm notes the company reported Q2 revenue of…
BioMarin price target raised to $60 from $50 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on BioMarin (BMRN) to $60 from $50 and keeps a Neutral rating on the shares post the Q2 report. While Voxzogo absorbed the…
BioMarin Pharmaceutical Earnings Call Transcript: Q2 2026
Q2 revenue grew 20% year-over-year to nearly $1 billion, driven by strong commercial execution and the successful Amicus integration. Raised full-year guidance for revenue and EPS, with VOXZOGO, GALAFOLD, and POMBILITI/OPFOLDA all on track for blockbuster status. Integration synergies and pipeline progress support a robust outlook.
BioMarin Pharmaceutical Slides: Q2 2026
BioMarin Pharmaceutical has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
BioMarin Pharmaceutical Earnings release: Q2 2026
BioMarin Pharmaceutical released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
BioMarin Pharmaceutical Quarterly report: Q2 2026
BioMarin Pharmaceutical has published its Q2 2026 quarterly earnings report on August 6, 2026.
BioMarin reports Q2 non-GAAP EPS $1.20, consensus 95c
Reports Q2 revenue $990M, consensus $932.04M. “This quarter, we executed strongly across our portfolio while rapidly integrating Amicus into BioMarin’s (BMRN) operations and advancing plans to acceler...
BioMarin Reports Second Quarter 2026 Financial and Operating Results
Second Quarter 2026 Total Revenues Increased 20% Year-over-year to $990 million Stronger Growth Expectations Drive Increased Guidance for Full-year 2026 Total Revenues, VOXZOGO®, and Non-GAAP Diluted ...
Spruce Biosciences appoints Jessica Cohen Pfeffer as VP, clinical development
Spruce Biosciences (SPRB) announced the appointment of Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development. Cohen Pfeffer joins Spruce from BioMarin Pharmaceutical (BMRN), where she s...